BC
ZYME icon

Boxer Capital’s Zymeworks ZYME Stock Holding History

Boxer Capital’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-165,000
Closed -$7.69M – 87
2020
Q3 		$7.69M Hold
165,000
– – 0.27% 59
2020
Q2 		$5.95M Buy
165,000
+140,000
+560% +$5.16M 0.26% 56
2020
Q1 		$887K Buy
+25,000
New +$1.02M 0.06% 62

Other funds holding ZYME

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Boxer Capital's ZYME Position: Q4 2020 in Review

Boxer Capital sold out of Zymeworks (ZYME) in Q4 2020, closing a stake of 165,000 shares — an estimated $7.69M sold.

Boxer Capital first reported a position in ZYME in Q1 2020 and held it in 3 quarters. The position peaked at $7.69M in Q3 2020. 138 funds tracked by Wall St. Rank hold ZYME as of Q4 2020.

  • Boxer Capital reported no remaining Zymeworks position as of Q4 2020 after selling out during the quarter.
  • Boxer Capital sold 165,000 Zymeworks shares in Q4 2020, an estimated $7.69M.
  • Boxer Capital first reported a position in Zymeworks in Q1 2020 and held it in 3 quarters.
  • Boxer Capital's Zymeworks position peaked at $7.69M in Q3 2020.
  • 138 funds tracked by Wall St. Rank held Zymeworks as of Q4 2020.

Based on Boxer Capital's 13F filing for Q4 2020, filed 16 Feb 2021.